This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
Cryptosporidiosis
+1

A Double-Blind, Placebo-Controlled Trial of Paromomycin for Treatment of Cryptosporidiosis in Patients With Advanced HIV Disease and CD4 Counts Under 150 Cells/mm3

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID)

About this trial

Last updated 4 years ago

Study ID

ACTG 192

Status

Completed

Type

Interventional

Phase

Phase 2

Placebo

No

Accepting

18-75 Years
13+ Years
All
All

Not accepting

Not accepting
Healthy Volunteers

What is this trial about?

To determine the effectiveness of oral paromomycin sulfate for 21 days compared to placebo in the treatment of cryptosporidiosis in patients with HIV infection. To evaluate the safety of oral paromomycin at two different doses. To explore whether paromomycin administered over a longer period provides additional benefit. In previous studies, patients with cryptosporidiosis demonstrated dramatic improvement with paromomycin therapy.

What are the participation requirements?

Yes

Inclusion Criteria

- Antiretroviral therapy.

- Macrolides for disseminated Mycobacterium avium.

- Atovaquone for toxoplasmosis.

- Other antimicrobials for concurrent infections.

- Lomotil, Imodium, or deodorized opium tincture in a standardized regimen for diarrhea. Patients must have:

- Advanced HIV disease.

- Diarrhea presumptively caused by Cryptosporidia.

No

Exclusion Criteria

- Hypersensitivity to aminoglycosides.

- Inability to swallow capsules.

- Active infection due to other enteric pathogens. Previous diagnosis of CMV or MAC infection permitted if patient is currently stabilized on a therapeutic regimen (clarithromycin up to 500 mg bid or azithromycin up to 600 mg daily).

- Other known causes for diarrhea (e.g., malabsorption syndrome, gastrointestinal Kaposi's sarcoma). Concurrent Medication: Excluded during the first 9 weeks of study:

- Agents with putative anticryptosporidial activity (such as spiramycin, diclazuril, letrazuril, or bovine colostrum).

- Octreotide acetate (Sandostatin).

- Antidiarrheals other than those specifically allowed.

- Clarithromycin if initiated at 500 mg or higher or azithromycin if initiated at 600 mg or higher. Prior Medication: Excluded:

- Paromomycin at > 1 g/day for >= 14 days prior to study entry. Excluded within 14 days prior to study entry:

- Agents with putative anticryptosporidial activity (such as spiramycin, diclazuril, letrazuril, or bovine colostrum), with the exception of macrolides that are permitted for other indications.

- Octreotide acetate (Sandostatin).

Locations

Location

Status